<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Zymeworks Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=34125></link><description><![CDATA[Zymeworks Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 23 Apr 2026 03:41:05 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/12/12_3554238800_20201202092455_1708634388.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress]]></title><link>https://www.newswire.co.kr/newsRead.php?no=897888</link><description><![CDATA[SINGAPORE--(Business Wire/Korea Newswire)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients with HER2‑expressing solid tumors in a mini oral presentation by Dr. Do-Youn Oh, study investigator and Professor at Seoul National University, ...]]></description><pubDate>Tue, 26 Nov 2019 10:09:37 +0900</pubDate></item></channel></rss>